Trial Profile
Impact of the MIC of piperacillin/tazobactam on outcome in patients with bacteraemia due to Enterobacteriaceae
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2015
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary)
- Indications Bacteraemia; Enterobacteriaceae infections
- Focus Therapeutic Use
- 16 Nov 2015 New trial record
- 03 Nov 2015 Results published in the Journal of Antimicrobial Chemotherapy